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Abstract: Over recent decades, due to the gradual rise in life expectancy and the consequent aging of the population, 
the incidence of some hematological malignancies most common in the elderly is expected to increase. In elderly cancer 
patients, the older age is an adverse prognostic factor because of specific age-related conditions, such as changes in 
cellular biology and reduced functional reserve in multiple organ systems, as well as in consequence of comorbidities. 
Some age-related pathological conditions, such as diabetes mellitus, renal failure, chronic obstructive pulmonary 
disease, cardiovascular dysfunction, liver disease and other disorders may predispose the elderlies to develop metabolic 
abnormalities. In the elderly, the occurrence of hematological malignancies can cause some metabolic disorders or 
worsen pre-existing dysmetabolic conditions that increase the outcomes of these patients. Hyperuricemia is the most 
common metabolic abnormality; hyperuricemia less commonly may be associated with hyperkalemia, 
hyperphosphatemia and hypocalcemia, in the framework of oncologic emergency that is the Tumor lysis syndrome. 
Hypercalcemia is relatively common in patients with multiple myeloma and adult T-cell Lymphoma. Cases of Syndrome of 
inappropriate secretion of antidiuretic hormone (SIADH) in patients with hematological malignancies have also been 
reported. Idiopathic hyperammonemia may occur in oncohematological patients after receiving intensive chemotherapy 
or following bone marrow transplantation. Moreover, there is evidence that patients with lymphoma, leukemia and 
multiple myeloma can develop Type B lactic acidosis. Non–islet cell tumor hypoglycemia and Hyperglycemia are other 
potential metabolic abnormalities occurring in patients with hematological malignancies. The pathogenesis of these 
metabolic disorders is often unclear and several theories have been postulated; possible mechanisms include: increase 
in neoplastic cell turnover and apoptosis, blast crisis, cytotoxic effects of chemotherapy, tumor secretion of hormones, 
peptides or cytokines, immune cross-reactivity between malignant and normal tissues, malignancy-induced enzyme 
dysfunction. Parenteral nutrition, sarcopenia, cachexia, stress, immune deficiency and infections could contribute. 
Although successful treatment of the underlying tumor often improves metabolic disorders, these conditions often worse 
prognosis and are associated with poor survival; thus it is important to consider early detection and effective treatment. 
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INTRODUCTION 
Over recent decades, due to the gradual rise in life 
expectancy and the consequent aging of the 
population, the incidence of some hematological 
malignancies, most common in the elderly, is expected 
to increase [1-3]. Actually, over the past decade, 
hematological malignant diseases, as Chronic B-cell 
lymphocytic leukemia, Multiple myeloma, Acute 
myeloid leukemia, Myelodysplastic syndrome and 
some types of Non-Hodgkin’s lymphoma, have been 
diagnosed with increasing frequency in patients older 
than 65 years [4].  
In elderly cancer patients, the advanced age is an 
adverse prognostic factor because of specific age-
related conditions, such as changes in cellular biology 
and reduced functional reserve in multiple organ 
systems, as well as in consequence of comorbidities 
[5]. In the elderly, the occurrence of hematological 
malignancies can cause some metabolic disorders or 
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worsen pre-existing dysmetabolic conditions, that 
increase the outcomes of these patients [6-8]. 
MATERIAL AND METHODS 
A review of literature has been carried out via Pub 
Med, using the search terms hematologic malignancies 
in conjunction with metabolic disorders and elderly. 
Searches were not limited by language or human 
subjects. All the found items, published in the last 10 
years (from July 2005 to July 2015), were analysed. 
Additional articles were selected from the 
bibliographies of the quoted references. 
RESULTS 
110 items were obtained: 24 case reports, 23 
clinical trials (1 randomized controlled trials), 13 
multicenter studies (6 comparative studies, 3 
evaluation studies, 2 observational studies), 12 
reviews, 1 editorial comment; the remaining items were 
prevalently small or short-term studies, research 
supports or other publication types. No meta-analysis, 
guidelines or consensus were found. Most of the data 
were deduced from retrospective analysis and by 
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careful assessment of the obtained items, in particular 
from case reports. Hyperuricemia is the most common 
metabolic abnormality in patients with hematological 
malignancies; less commonly it may be associated with 
hyperkalemia, hyperphosphatemia and hypocalcemia 
in a framework of Tumor lysis syndrome. 
Hypercalcemia, Hypoglycemia and Hyperglycemia are 
relatively common. Syndrome of inappropriate 
secretion of antidiuretic hormone (SIADH), Idiopathic 
hyperammonemia and Type B lactic acidosis are less 
frequently reported.  
DISCUSSION 
The management of hematological malignant 
diseases is particularly difficult in the elderlies because 
these patients may have very variable health status, 
geriatric syndrome and comorbidities [9-11]. Some 
age-related pathological conditions, such as diabetes 
mellitus, renal failure, chronic obstructive pulmonary 
disease, cardiovascular dysfunction, liver disease and 
other disorders, may predispose the elderly patient to 
develop metabolic disorders [12-19]; long-term 
parenteral nutrition, sarcopenia, cachexia, stress, 
immune deficiency and infections could contribute as 
predisposing factors [20-25]. On the other hand, 
metabolic alterations are also a common feature in 
hematological malignant diseases. Metabolic disorders 
are typically detected in elderly patients after 
hematological malignancies diagnosis, but in some 
instances these alterations are manifest before tumor 
diagnosis; then the development of these disorders 
does not necessarily correlate with cancer stage. 
Although several metabolic disorders arise during 
chemotherapy or following stem cell transplantation, in 
many cases successful treatment of the underlying 
malignancy often improves metabolic disorders. 
Nevertheless these conditions worsen prognosis and 
are associated with poor survival, thus effective 
diagnosis and treatment of metabolic disorders may 
substantially improve overall clinical outcomes; for this 
reason it is important to consider early diagnosis and 
prompt treatment [7, 26-27]. 
This review focuses on the pathophysiologic 
mechanisms and diagnosis of the most common 
metabolic disorders in elderly patients with 
hematological malignancies; treatment options are also 
discussed. 
Hyperuricemia and Tumor lysis syndrome 
Hyperuricemia is a common metabolic disorder in 
patients with hematological malignant diseases. Uric 
acid is the final oxidation product of purine metabolism 
and increases in its plasma level can be realized in 
these patients by rise in neoplastic cell turnover and 
apoptosis, blast crisis and breakdown of malignant 
cells following chemotherapy, as well as it can be 
caused by insufficient urinary excretion [28-30]. Less 
commonly, as a direct consequence of neoplastic 
disruption, intracellular ions, nucleic acids, proteins and 
their metabolites are released into the plasma causing 
the framework of the Tumor lysis syndrome (TLS). 
Characteristic metabolic abnormalities of this oncologic 
emergency are hyperuricemia (> 8 mg/dL), 
hyperkalemia (> 6 mEq/dL), hyperphosphatemia (> 4, 5 
mg/dL) and hypocalcemia (< 7 mg/dL) [31]. In more 
serious cases, large amounts of intracellular contents 
are released so abrupt that the normal homeostatic 
mechanisms are rapidly overwhelmed and TLS leads 
to acute renal failure and other complications as 
seizures, arrhythmias and sudden death [32-33]. TLS is 
observed most frequently in patients with Acute 
lymphoblastic leukemia, high-grade Lymphomas and 
Burkitt’s lymphoma, although it may also occur in other 
hematologic malignancies commonly after the initiation 
of chemotherapy; rarely, TLS can arise spontaneously 
in oncohematological patients prior to the onset of 
chemotherapy [34, 35]. TLS is a potentially life-
threatening metabolic disorder and the identification of 
patients at risk is essential. Vigorous hydration and 
anti-hyperuricemic therapy, at least 2–3 days before 
the initiation of cytotoxic therapy, remain the 
cornerstones of TLS prevention. The treatment 
involves intravenous hydration with approximately 3 
L/m2/day and correction of acid-base imbalances; 
hyperkalemia, hyperphosphatemia and hypocalcemia 
should be treated expediently according to standard 
measures [32]. Hyperuricemia should be treated with 
Allopurinol, that prevents new uric acid formation by 
inhibiting xanthine oxidase, or with Rasburicase, a 
recombinant urate oxidase, that converts pre-existing 
uric acid to allantoin [30, 36, 37]. Urinary alkalinization 
is no longer recommended and remains controversial 
and the role of loop diuretics is not based on solid data, 
thus it should be approached on individual basis in 
patients at increased risk of fluid overload. Patients 
who have significant acute uremia, fluid overload or 
severe electrolyte abnormalities, should start 
hemodialysis as soon as possible; continuous vital 
signs monitoring is necessary [32]. 
Hypercalcemia 
Multiple myeloma and adult T-cell 
leukemia/lymphoma are hematological malignant 
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diseases commonly associated with Hypercalcemia 
[26, 38]. Three main mechanisms can be responsible 
for hypercalcemia in these patients: osteolytic 
metastases with local release of cytokines, including 
osteoclasts activating factors, tumor secretion of 
parathyroid hormone-related protein (PTHrP), and 
tumor production of 1,25-dihydroxyvitamin D (calcitriol) 
or cytokines such as tumor necrosis factor (TNF), 
Interleukin 1 (IL-1) and Transforming growth factor 
alpha (TGF-α). Frequent clinical manifestations of 
malignancy related hypercalcemia are: nausea, 
vomiting, ileus, anorexia, dehydration, renal failure, 
muscle weakness, psychosis, lethargy, coma, and 
cardiac abnormalities as short QT interval and atrial or 
ventricular arrhythmia. Thus hypercalcemia may 
become a life threatening metabolic disorder in 
oncohematological patients [39, 40].  
The optimal approach to hypercalcemia related to 
hematological malignant diseases is to treat the 
underlying tumor; nevertheless, fluid intravenous 
hydration with normal saline should be the initial 
treatment. The hydro-saline replenishment corrects the 
dehydration and increases the glomerular filtration rate. 
Although loop diuretics inhibit renal calcium 
reabsorption, these agents should not be routinely 
used for all hypercalcemic patients in order not to 
deteriorate the dehydration; these drugs may be added 
after adequate fluid replenishment. Intravenous 
Bisphosphonates are generally established as first-line 
therapy after volume expansion; these agents have 
been widely used because of inhibitory effect on bone 
resorption mediated by osteoclasts. Calcitonin, that 
inhibits bone resorption and increases the renal 
calcium excretion, is a useful adjunctive initial therapy. 
The hypocalcemic effect of calcitonin appears rapidly 
but it is often partial and temporary [41]. Of late, there 
is growing interest in the use of Denosumab, a 
monoclonal antibody against the receptor activator of 
nuclear factor-κB ligand (RANKL), in patients with bone 
metastases. The efficacy of Denosumab for treating 
malignant hypercalcemia is currently being evaluated in 
clinical trials [42, 43]. 
Hypoglycemia 
There are evidences that in patients with Multiple 
myeloma, non-Hodgkin's lymphoma and Hodgkin's 
disease can occur Hypoglycemia. Production and 
release of insulin-like substances by cancer cells is the 
most recognized pathogenetic mechanism to explain 
hypoglycemia in these patients. Tumor cell 
overproduction of Insulin-like Growth Factor-2 (IGF-2), 
or its high-molecular-weight precursor (big IGF2), has 
been proven in some hematological malignant 
diseases, in association with consequent reduction in 
the blood glucose level [44-47]. Tumor oversecretion of 
IGF-2, or big IGF-2, is the main etiologic factor 
responsible for a specific clinical entity, known as Non-
islet-cell tumor hypoglycemia (NICTH), that typically 
affects elderly patients with advanced cancer [48]. 
Other pathogenetic mechanisms for hypoglycemia are 
cancer production of autoantibodies to insulin or its 
receptor, Insulin-like Growth Factor-1 (IGF-1) tumor 
secretion and, more rarely, secretion of glucagon-like 
peptide-1 (GLP-1) or ectopic insulin release. In 
oncohematological patients, hypoglycemia may also be 
due to increased glucose consumption by the tumor 
mass and its metastases, as well as in cases with 
massive liver infiltration [44, 49-53]. Iatrogenic 
hypoglycemia has been also reported in patients 
treated with rituximab [54], tyrosine kinase inhibitors 
[55] and oral purine analogues [56], as well as in those 
receiving trimethoprim/sulfamethoxazole [57] and 
levofloxacin [58]. The exact mechanism of 
chemotherapy-induced hypoglycemia is not clear, while 
in antibiotic-associated hypoglycemia it has been 
suggested a sulfonylurea-like effect [57]. In non 
diabetic subjects hypoglycemia is usually diagnosed 
when venous plasma glucose is <55  mg/dl in presence 
of symptoms, signs, or both consistent with 
hypoglycemia, with resolution of those after raising 
plasma glucose concentration. In addition to low serum 
glucose levels during acute episodes, NICTH is 
characterized by an elevated molar IGF-2:IGF-1 ratio 
[52]. 
In oncohematological patients, the optimal 
therapeutic approach to hypoglycemia is to treat the 
underlying malignancy. When it is not feasible, the aim 
of therapy is to maintain normal blood glucose levels. 
In acute hypoglycemia parenteral dextrose exerts 
immediate effect on blood glucose, while oral glucose 
administration raises glycemia in 15 to 30 minutes. For 
recurrent or chronic hypoglycemia, long-term 
management includes intravenous corticosteroids, 
glucagon and, in selected cases, octreotide, diazoxide 
or growth hormone [52, 53]. 
Hyperglycemia 
Oncohematological patients are at high risk for 
Hyperglycemia because of several reasons such as 
prolonged glucocorticoid treatment, immune deficiency 
state and immunosuppressive therapy, iron overload 
from repeated transfusion, transplant proceedings, 
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frequent infections, cytokines overproduction, total 
parenteral nutrition, sarcopenia, cachexia, and medical 
stress [59]. These permanent or intercurrent factors 
can further worsen a pre-existing insulin resistance in 
patients who already have type 2 diabetes, as well as 
these factors can increase insulin requirement in 
previously normoglycemic patients. In patients with 
hematological malignant diseases hyperglycemia is 
associated with poor outcomes including increased risk 
of infection, comorbidities and organ dysfunction, 
shorter duration of remission and, in more serious 
cases, less eligibility for intensive chemotherapy, 
higher incidence of graft-versus-host disease and 
increased mortality [59-62]. Plasma hyperosmolality, 
ketoacidosis and lactic acidosis are potential life-
threatening complication of severe untreated 
hyperglycemia [63-65] that can precipitate or worsen 
other metabolic disorders in elderly patients with 
hematological malignancy. Intravenous hydration, 
correction of electrolyte imbalance and pH alteration, 
intensive insulin therapy are the first-line treatment of 
acute severe hyperglycemia [66]. Oral hypoglycemic 
agents, unless contraindicated, alternatively could also 
be used to long-term control of chronic mild-moderate 
hyperglycemia in type 2 patients with hematological 
malignant diseases [67].  
Type B Lactic Acidosis 
Type B lactic acidosis is a rare complication of 
malignancy, for the first time reported in patients with 
Acute leukemia by Field et al [68]; since then, this 
metabolic disorder has been described more often in 
patients with hematological malignant diseases, mainly 
non-Hodgkin’s lymphoma and Acute lymphocytic 
leukemia [69-72]. The exact cause of lactic acidosis in 
hematological malignancy remains unknown and 
several theories have been suggested to explain the 
mechanisms involved in the development of this 
metabolic disorder in oncohematological patients. A 
possible mechanisms includes an increase in the 
glycolytic rate in cancer cells, in part due to aberrant 
insulin-like growth factor signaling system that induces 
the overexpression of hexokinase II, the rate-limiting 
enzyme involved in glycolysis [73]. Moreover, in the 
tumor cells the avid consumption of glucose through 
the glycolytic pathway, even in presence of normal 
oxygen concentrations, causes overproduction of 
lactate; this metabolic process is known as aerobic 
glycolysis or Warburg effect [74, 75]. These 
mechanisms could also explain the occurrence of 
hypoglycemia in patients with Type B lactic acidosis, as 
reported in some cases of non-Hodgkin’s lymphoma 
[45, 76, 77]. The overproduction of lactate could also 
be related to deficiency of thiamine that leads to 
pyruvate accumulation with increase in lactate 
production. Type B lactic acidosis can also be caused 
by a decreased hepatic clearance of lactate, so that 
oncohematological patients with extensive hepatic 
infiltration are at increased risk of developing this 
metabolic alteration. At last, the embolization of cancer 
cells into the microvasculature, causing tissutal 
hypoperfusion with increase of anaerobic metabolism, 
could be another possible mechanism of lactic 
acidosis. Type B lactic acidosis is defined as lactic acid 
levels above 5 mmol/L and pH less than 7,30 in whole 
blood [74, 78] and it can be a rapidly fatal metabolic 
complication if not promptly recognized and treated 
with emergency chemotherapy; therefore the 
immediate treatment of the underlying malignancy with 
chemotherapy is the first-line strategy [78]. Other 
treatment modalities include dialysis, intravenous 
thiamine supplementation, sodium bicarbonate 
infusion, and supportive management [74, 78]. 
However the outcome of the majority of patients with 
Type B lactic acidosis may be invariably fatal, 
suggesting that lactic acidosis may serve as marker of 
poor prognosis [78]. 
Idiopathic Hyperammonemia 
Idiopathic hyperammonemia is characterized by 
sudden increase in blood ammonia levels with no other 
obvious etiology, normal liver function tests and in the 
absence of inborn errors of metabolism or other 
identifiable causes; therefore Idiopathic 
hyperammonemia is a diagnosis of exclusion and all 
other causes needs to be ruled out. This metabolic 
disorder is clinically characterized by neurological 
deterioration which mostly results in intractable coma; 
cerebral edema is common in these patients due to the 
osmotic effect of intracellular accumulation of 
glutamine, the major metabolite of ammonia in the 
brain [79]. Idiopathic hyperammonemia has been 
reported in some elderly patients with hematological 
malignant diseases [79, 80], following intensive 
chemotherapy [79, 81] as well as following bone 
marrow and stem cell transplantation [82,83]. Several 
chemotherapeutic agents may be responsible for this 
metabolic abnormality: cytarabine, daunomycin, 
cyclophosphamide, vincristine, etoposide, 
asparaginase, busulfan, and methotraxate are mainly 
involved; however there is some evidence of 
correlation between Idiopathic hyperammonemia and 
chemotherapy with vinorelbine, topotecan, cisplatin, 
rituximab, melphalan, and carboplatin. Cases of 
Idiopathic hyperammonemia in patients receiving 
32    World Journal of Oncology Research, 2015, Vol. 2 Carella et al. 
allogeneic or autologous hematopoietic stem cell 
transplantation are also reported [82-86]. The 
pathogenesis of idiopathic hyperammonemia is unclear 
and was hypothesized to be multifactorial. The acute 
elevations of ammonia and glutamine suggest acquired 
urea cycle defect or more general mitochondrial 
dysfunction induced by chemotherapeutic agents [79, 
81, 84, 86]. Several hypotheses have been proposed, 
including chemotherapy-induced urea cycle enzymes 
deficiency, as carbamoyl phosphate synthetase 1, or 
ornithine transcarbamylase, or N-acetylglutamate 
synthase, and inhibition of oxidative phosphorylation 
complexes I and V in liver tissue. Some malignancy-
related conditions, very common in oncohematological 
elderly patients, as sepsis and infections, particularly 
with urea-splitting bacteria, gastrointestinal bleeding, 
hyporexia, total parenteral nutrition, sarcopenia, protein 
catabolism and catabolic state could also contribute to 
hyperammonemia [86-90].  
Therapeutic aim in patients with Idiopatic 
hyperammonemia is to correct the biochemical 
abnormalities and ensure adequate nutritional intake; 
treatment involves compounds that increase the 
removal of nitrogen waste. Dietary protein restriction, 
oral lactulose and ammonia-trapping treatment with 
intravenous and oral nitrogen scavengers, as sodium 
phenylacetate and sodium benzoate, are usually able 
to normalize the ammonia levels. In non-responders 
patients the expanded use of Carglumic acid might be 
warranted and intermittent hemodialysis may be 
requested in selected cases [91, 92]. 
Syndrome of Inappropriate Secretion of 
Antidiuretic Hormone (SIADH) 
The Syndrome of inappropriate antidiuretic hormone 
secretion (SIADH) is characterized by hypo-osmotic 
euvolemic hyponatremia (< 134 mEq/L) and increased 
urine osmolality (> 100 mOsm/kg); in cancer patients 
this syndrome arises from tumor cell production of 
antidiuretic hormone (ADH), also known as arginine 
vasopressin, and atrial natriuretic peptide [93-94]. 
SIADH has been reported in patients with Large cell 
anaplastic lymphoma and M4 Acute myeloid leukemia 
[95-97], as well as after stem cells transplantation [98, 
99] and during high-dose chemotherapy with some 
agents as cyclophosphamide and vincristine [100, 101]. 
The clinical signs of SIADH vary with the degree and 
rapidity of onset of hyponatremia, so that the patients 
can manifest nausea, anorexia, headache, fatigue, 
muscle cramps, lethargy, seizures, respiratory 
depression, coma [102]. The optimal therapy for 
oncohematological SIADH is treatment of the 
underlying malignancy which can normalize sodium 
level; other therapeutic options in correcting 
hyponatremia are fluid restriction (usually <1000 mL/d), 
intravenous hypertonic saline, adequate salt and 
protein intake [93, 94, 102]. Administration of 
vasopressin V2-receptor antagonists, as Tolvaptan, 
results in improvement of serum sodium levels. These 
drugs, which block arginine vasopressin binding to 
receptors in the renal ducts, act as aquaretic agents 
increasing the excretion of free water and retaining 
sodium [103]. Since 2009 vasopressin receptor 
antagonists can be used in many clinical situations 
resulting in hyponatremia, including congestive heart 
failure, cirrhosis and SIADH, but efficacy and safety 
data in cancer patients are lacking. Therefore these 
agents are generally considered only after failure of 
fluid restriction and other therapeutic options [104,105].  
CONCLUSION 
As consequence of age-related comorbidities, older 
people may have higher risk to develop metabolic 
disorders; in addition, a wide variety of metabolic 
alterations can be associated with hematological 
malignant diseases, increasing poor outcomes of these 
patients. Intensive chemotherapy and proceedings 
transplantation are often responsible for metabolic 
disorders, so that clinicians should consider these 
potential adverse conditions before starting standard 
intensive treatment protocols in these patients. 
Moreover, some dysmetabolic conditions are 
potentially life-threatening and could be serious 
medical emergencies. Although the immediate 
treatment of the underlying hematological malignancy 
should result in clearing of the metabolic disturbance, 
in several cases intensive and specific therapeutic 
approaches are requested. Prevention and early 
detection of these metabolic disorders are of crucial 
importance and could help improve the management of 
elderly oncohematological patients. In our research we 
have assessed 23 clinical trials, 1 randomized 
controlled trial and 13 multicenter studies, most of 
which were not designed to evaluate the metabolic 
outcomes of the enrolled patients. It would certainly be 
advisable to start prospective and observational 
multicenter controlled studies, aimed at giving a more 
accurate and actual dimension of these metabolic 
complications.  
REFERENCES 
[1] Wang H, Dwyer-Lindgren L, Lofgren KT, Rajaratnam JK, 
Marcus JR, Levin-Rector A, et al. Age-specific and sex-
specific mortality in 187 countries, 1970-2010: a systematic 
Metabolic Disorders in Elderly Patients with Hematologic Malignancies World Journal of Oncology Research, 2015, Vol. 2    33 
analysis for the Global Burden of Disease Study 2010. 
Lancet. 2012; 380(9859): 2071-94. 
http://dx.doi.org/10.1016/S0140-6736(12)61719-X 
[2] Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA 
Cancer J Clin. 2010; 60(5): 277 
http://dx.doi.org/10.3322/caac.20073 
[3] Yancik RM, Ries LA. Cancer in the older person: an 
international issue in an aging world. Semin Oncol. 2004; 31: 
128-36. 
http://dx.doi.org/10.1053/j.seminoncol.2003.12.024 
[4] Rodriguez-Abreu D, Bordoni A, Zucca E. Epidemiology of 
hematological malignancies. Ann Oncol. 2007; 18(Suppl 1): 
i3-i8. 
http://dx.doi.org/10.1093/annonc/mdl443 
[5] Balducci L, Extermann M. Management of cancer in the older 
person: a practical approach. Oncologist. 2000; 5(3): 224-37. 
http://dx.doi.org/10.1634/theoncologist.5-3-224 
[6] Leni Z, Parakkal G, Arcaro A. Emerging metabolic targets in 
the therapy of hematological malignancies. Biomed Res Int. 
2013; 2013: 946206.  
http://dx.doi.org/10.1155/2013/946206 
[7] Flombaum CD. Metabolic emergencies in the cancer patient. 
Semin Oncol. 2000; 27(3): 322-34. 
[8] Lee JH, Choi SJ, Lee JH, Kim SE, Seol M, Lee YS, et al. 
Severe metabolic abnormalities after allogeneic 
hematopoietic cell transplantation. Bone Marrow Transplant. 
2005; 35(1): 63-9. 
http://dx.doi.org/10.1038/sj.bmt.1704708 
[9] Caillet P, Laurent M, Bastuji-Garin S, Liuu E, Culine S, 
Lagrange JL, et al. Optimal management of elderly cancer 
patients: usefulness of the Comprehensive Geriatric 
Assessment. Clin Interv Aging. 2014; 9: 1645-60. 
[10] Malaguarnera M, Frazzetto PM, Erdogan O, Cappellani A, 
Cataudella E, Berretta M. Geriatric evaluation of oncological 
elderly patients. Anticancer Agents Med Chem. 2013; 13(9): 
1300-9. 
http://dx.doi.org/10.2174/18715206113136660343 
[11] Balducci L. Management of cancer in the elderly. Oncology 
(Williston Park). 2006; 20(2): 135-43; discussion 144, 146, 
151-2. 
[12] Mazza AD. Insulin resistance syndrome and glucose 
dysregulation in the elderly. Clin Geriatr Med. 2008; 24(3): 
437-54. 
http://dx.doi.org/10.1016/j.cger.2008.03.006 
[13] Bach LA, Hale LJ. Insulin-like growth factors and kidney 
disease. Am J Kidney Dis. 2015; 65(2): 327-36. 
http://dx.doi.org/10.1053/j.ajkd.2014.05.024 
[14] Arcopinto M, Cittadini A. Hormonal alterations in heart failure: 
anabolic impairment in chronic heart failure - diagnostic, 
prognostic and therapeutic issues. Front Horm Res. 2014; 
43: 57-69. 
[15] Iozzo P. Metabolic toxicity of the heart: insights from 
molecular imaging. Nutr Metab Cardiovasc Dis. 2010; 20(3): 
147-56. 
http://dx.doi.org/10.1016/j.numecd.2009.08.011 
[16] Carlin BW. COPD and associated comorbidities: a review of 
current diagnosis and treatment. Postgrad Med. 2012; 
124(4): 225-40. 
http://dx.doi.org/10.3810/pgm.2012.07.2582 
[17] Faner R, Cruz T, López-Giraldo A, Agustí A. Network 
medicine, multimorbidity and the lung in the elderly. Eur 
Respir J. 2014; 44(3): 775-88. 
http://dx.doi.org/10.1183/09031936.00078714 
[18] Sheedfar F, Di Biase S, Koonen D, Vinciguerra M. Liver 




[19] Ghouri N, Preiss D, Sattar N. Liver enzymes, nonalcoholic 
fatty liver disease, and incident cardiovascular disease: a 
narrative review and clinical perspective of prospective data. 
Hepatology. 2010; 52(3): 1156-61. 
http://dx.doi.org/10.1002/hep.23789 
[20] Btaiche IF, Khalidi N. Metabolic complications of parenteral 
nutrition in adults, part 1. Am J Health Syst Pharm. 2004; 
61(18): 1938-49. 
[21] Btaiche IF, Khalidi N. Metabolic complications of parenteral 
nutrition in adults, Part 2. Am J Health Syst Pharm. 2004; 
61(19): 2050-7; quiz 2058-9. 
[22] Evans W. Functional and metabolic consequences of 
sarcopenia. J Nutr. 1997; 127(5 Suppl): 998S-1003S. 
[23] Argilés JM, López-Soriano FJ, Toledo M, Betancourt A, 
Serpe R, Busquets S. The cachexia score (CASCO): a new 
tool for staging cachectic cancer patients. J Cachexia 
Sarcopenia Muscle. 2011; 2(2): 87-93. 
http://dx.doi.org/10.1007/s13539-011-0027-5 
[24] Preiser JC, Ichai C, Orban JC, Groeneveld AB. Metabolic 
response to the stress of critical illness. Br J Anaesth. 2014; 
113(6): 945-54. 
http://dx.doi.org/10.1093/bja/aeu187 
[25] Willig AL, Overton ET. Metabolic consequences of HIV: 
pathogenic insights. Curr HIV/AIDS Rep. 2014; 11(1): 35-44. 
http://dx.doi.org/10.1007/s11904-013-0191-7 
[26] Silverman P, Distelhorst CW. Metabolic emergencies in 
clinical oncology. Semin Oncol. 1989; 16(6): 504-15. 
[27] Spinazze S, Schrijvers D. Metabolic emergencies. Crit Rev 
Oncol Hematol. 2006; 58: 79-89. 
http://dx.doi.org/10.1016/j.critrevonc.2005.04.004 
[28] Cairo MS. Prevention and treatment of hyperuricemia in 
hematological malignancies. Clin Lymphoma. 2002; 3 Suppl 
1: S26-31. 
http://dx.doi.org/10.3816/CLM.2002.s.012 
[29] Oka Y, Tashiro H, Sirasaki R, Yamamoto T, Akiyama N, 
Kawasugi K, et al. Hyperuricemia in hematologic 
malignancies is caused by an insufficient urinary excretion. 
Nucleosides Nucleotides Nucleic Acids. 2014; 33(4-6): 434-8. 
http://dx.doi.org/10.1080/15257770.2013.872274 
[30] Tsimberidou AM, Keating MJ. Hyperuricemic syndromes in 
cancer patients. Contrib Nephrol. 2005; 147: 47-60. 
[31] Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, 
Schreiber MJ. Pathophysiology, clinical consequences, and 
treatment of tumor lysis syndrome. Am J Med. 2004; 116(8): 
546-54. 
http://dx.doi.org/10.1016/j.amjmed.2003.09.045 
[32] Mirrakhimov AE, Voore P, Khan M, Ali AM. Tumor lysis 
syndrome: A clinical review. World J Crit Care Med. 2015; 
4(2): 130-8. 
http://dx.doi.org/10.5492/wjccm.v4.i2.130 
[33] Karagiannis A, Tsorlalis I, Kakafika A, Pateinakis P, Perifanis 
V, Harsoulis F. Acute renal failure due to tumor lysis 
syndrome in a patient with non-Hodgkin's lymphoma. Ann 
Hematol. 2005; 84(5): 343-6. 
http://dx.doi.org/10.1007/s00277-004-0984-2 
[34] Firwana BM, Hasan R, Hasan N, Alahdab F, Alnahhas I, 
Hasan S, et al. Tumor lysis syndrome: a systematic review of 
case series and case reports. Postgrad Med. 2012; 124(2): 
92-101. 
http://dx.doi.org/10.3810/pgm.2012.03.2540 
[35] Levine AM. Challenges in the management of Burkitt's 
lymphoma. Clin Lymphoma. 2002; 3 Suppl 1: S19-25. 
http://dx.doi.org/10.3816/CLM.2002.s.011 
[36] Dinnel J, Moore BL, Skiver BM, Bose P. Rasburicase in the 
management of tumor lysis: an evidence-based review of its 
place in therapy. Core Evid. 2015; 10: 23-38. 
[37] Lopez-Olivo MA, Pratt G, Palla SL, Salahudeen A. 
Rasburicase in tumor lysis syndrome of the adult: a 
34    World Journal of Oncology Research, 2015, Vol. 2 Carella et al. 
systematic review and meta-analysis. Am J Kidney Dis. 
2013; 62(3): 481-92. 
http://dx.doi.org/10.1053/j.ajkd.2013.02.378 
[38] Stewart AF. Hypercalcemia associated with cancer. N Engl J 
Med. 2005; 352: 373-379. 
http://dx.doi.org/10.1056/NEJMcp042806 
[39] Rosner MH, Dalkin AC. Onco-nephrology: the 
pathophysiology and treatment of malignancy-associated 
hypercalcemia. Clin J Am Soc Nephrol. 2012; 7(10): 1722-9. 
http://dx.doi.org/10.2215/CJN.02470312 
[40] Clines GA. Mechanisms and treatment of hypercalcemia of 
malignancy. Curr Opin Endocrinol Diabetes Obes. 2011; 
18(6): 339-46. 
http://dx.doi.org/10.1097/MED.0b013e32834b4401 
[41] Lumachi F, Brunello A, Roma A, Basso U. Medical treatment 
of malignancy-associated hypercalcemia. Curr Med Chem. 
2008; 15: 415-421. 
http://dx.doi.org/10.2174/092986708783497346 
[42] Maier JD, Levine SN. Hypercalcemia in the Intensive Care 
Unit: A Review of Pathophysiology, Diagnosis, and Modern 
Therapy. J Intensive Care Med. 2015; 30(5): 235-52. 
http://dx.doi.org/10.1177/0885066613507530 
[43] Castellano D, Sepulveda JM, García-Escobar I, Rodriguez-
Antolín A, Sundlöv A, Cortes-Funes H. The role of RANK-
ligand inhibition in cancer: the story of denosumab. 
Oncologist. 2011; 16(2): 136-45. 
http://dx.doi.org/10.1634/theoncologist.2010-0154 
[44] Waldron-Lynch F, Inzucchi SE, Menard L, Tai N, Preston-
Hurlburt P, Hui P, et al. Relapsing and remitting severe 
hypoglycemia due to a monoclonal anti-insulin antibody 
heralding a case of multiple myeloma. J Clin Endocrinol 
Metab. 2012; 97(12): 4317-23. 
http://dx.doi.org/10.1210/jc.2012-2388 
[45] Elhomsy GC, Eranki V, Albert SG, Fesler MJ, Parker SM, 
Michael AG, et al. "Hyper-warburgism," a cause of 
asymptomatic hypoglycemia with lactic acidosis in a patient 
with non-Hodgkin's lymphoma. J Clin Endocrinol Metab. 
2012; 97(12): 4311-6. 
http://dx.doi.org/10.1210/jc.2012-2327 
[46] Soares-Welch CV, Zeldenrust SR, Conover CA, Grant CS, 
Service FJ. Hodgkin's lymphoma manifesting with 
hypoglycemia. Endocr Pract. 2003; 9(1): 96-7. 
http://dx.doi.org/10.4158/EP.9.1.96 
[47] Snowden JA, Greaves M, Page K. Reversal of diabetes 
associated with escape of myeloma: evidence for 
inappropriate IGF-II secretion. Br J Haematol. 1994; 87(1): 
202-4. 
http://dx.doi.org/10.1111/j.1365-2141.1994.tb04894.x 
[48] Nayar MK, Lombard MG, Furlong NJ, McNulty SJ, Hardy KJ, 
Vora J. Diagnosis and management of nonislet cell tumor 
hypoglycemia: case series and review of the literature. 
Endocrinologist. 2006; 16(4): 227-230. 
http://dx.doi.org/10.1097/01.ten.0000226008.02412.0b 
[49] Halsall DJ, Mangi M, Soos M, Fahie-Wilson MN, Wark G, 
Mainwaring-Burton R, et al. Hypoglycemia due to an insulin 
binding antibody in a patient with an IgA-kappa myeloma. J 
Clin Endocrinol Metab. 2007; 92(6): 2013-6. 
http://dx.doi.org/10.1210/jc.2007-0075 
[50] Kulkarni A, Zlabek J, Farnen J, Capla R. Recurrent 
hypoglycemia and hypothermia in a patient with Hodgkin's 
disease. Haematologica. 2006; 91(12 Suppl): ECR50. 
[51] Nauck MA, Reinecke M, Perren A, Frystyk J, Berishvili G, 
Zwimpfer C, et al. Hypoglycemia due to paraneoplastic 
secretion of insulin-like growth factor-I in a patient with 
metastasizing large-cell carcinoma of the lung. J Clin 
Endocrinol Metab. 2007; 92(5): 1600. 
http://dx.doi.org/10.1210/jc.2006-2573 
[52] Iglesias P, Díez JJ. Management of endocrine disease: a 
clinical update on tumor-induced hypoglycemia. Eur J 
Endocrinol. 2014; 170(4): R147-57. 
http://dx.doi.org/10.1530/EJE-13-1012 
[53] Bodnar TW, Acevedo MJ, Pietropaolo M. Management of 
non-islet-cell tumor hypoglycemia: a clinical review. J Clin 
Endocrinol Metab 2014; 99: 713. 
[54] Hussain BM, Geetha N, Lali V, Pandey M. Rituximab induced 
hypoglycemia in non-Hodgkin's lymphoma. World J Surg 
Oncol. 2006; 4: 89. 
http://dx.doi.org/10.1186/1477-7819-4-89 
[55] Agostino NM, Chinchilli VM, Lynch CJ, Koszyk-Szewczyk A, 
Gingrich R, Sivik J, et al. Effect of the tyrosine kinase 
inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on 
blood glucose levels in diabetic and nondiabetic patients in 
general clinical practice. J Oncol Pharm Pract. 2011; 17(3): 
197-202. 
http://dx.doi.org/10.1177/1078155210378913 
[56] Bay A, Oner AF, Cesur Y, Dogan M, Etlik O, Sanli F. 
Symptomatic hypoglycemia: an unusual side effect of oral 
purine analogues for treatment of ALL. Pediatr Blood Cancer. 
2006; 47(3): 330-1. 
http://dx.doi.org/10.1002/pbc.20582 
[57] Nunnari G, Celesia BM, Bellissimo F, Tosto S, La Rocca M, 
Giarratana F, et al. Trimethoprim-sulfamethoxazole-
associated severe hypoglycaemia: a sulfonylurea-like effect. 
Eur Rev Med Pharmacol Sci. 2010; 14(12): 1015-8. 
[58] Parra-Riffo H, Lemus-Pe-aloza J. Severe levofloxacin-
induced hypoglycaemia: a case report and literature review. 
Nefrologia. 2012; 32(4): 546-7. 
[59] Healy SJ, Dungan KM. Hyperglycemia in patients with 
hematologic malignancies. Curr Diab Rep. 2015; 15(3): 8. 
http://dx.doi.org/10.1007/s11892-015-0581-x 
[60] Daniel BT. Glycemic crises in patients with hematologic 
malignancies. Crit Care Nurs Clin North Am. 2000; 12(3): 
297-305. 
[61] Brunello A, Kapoor R, Extermann M. Hyperglycemia during 
chemotherapy for hematologic and solid tumors is correlated 
with increased toxicity. Am J Clin Oncol. 2011; 34(3): 292-6. 
http://dx.doi.org/10.1097/COC.0b013e3181e1d0c0 
[62] Olausson JM, Hammer MJ, Brady V. The impact of 
hyperglycemia on hematopoietic cell transplantation 
outcomes: an integrative review. Oncol Nurs Forum. 2014; 
41(5): E302-12. 
http://dx.doi.org/10.1188/14.ONF.E302-E312 
[63] Maletkovic J, Drexler A. Diabetic ketoacidosis and 
hyperglycemic hyperosmolar state. Endocrinol Metab Clin 
North Am. 2013; 42(4): 677-95. 
http://dx.doi.org/10.1016/j.ecl.2013.07.001 
[64] Pasquel FJ, Umpierrez GE. Hyperosmolar hyperglycemic 
state: a historic review of the clinical presentation, diagnosis, 
and treatment. Diabetes Care. 2014; 37(11): 3124-31. 
http://dx.doi.org/10.2337/dc14-0984 
[65] Cox K, Cocchi MN, Salciccioli JD, Carney E, Howell M, 
Donnino MW. Prevalence and significance of lactic acidosis 
in diabetic ketoacidosis. J Crit Care. 2012; 27(2): 132-7. 
http://dx.doi.org/10.1016/j.jcrc.2011.07.071 
[66] Beltran G. Diabetic emergencies: new strategies for an old 
disease. Emerg Med Pract. 2014; 16(6): 1-19; quiz 19-20. 
[67] Brietzke SA. Oral antihyperglycemic treatment options for 
type 2 diabetes mellitus. Med Clin North Am. 2015; 99(1): 87-
106. 
http://dx.doi.org/10.1016/j.mcna.2014.08.012 
[68] Field M, Block JB, Rall DP. Lactic acidosis in acute leukemia. 
Clin Res. 1963; 11: 193-7. 
[69] De Raes EA, Benoit DD, Depuydt PO, Offner F, Nollet J, 
Vantilborgh AK, et al. Early recognition of malignant lactic 
acidosis in clinical practice: report on 6 patients with 
haematological malignancies. Acta Clin Belg. 2012; 67(5): 
347-51. 
Metabolic Disorders in Elderly Patients with Hematologic Malignancies World Journal of Oncology Research, 2015, Vol. 2    35 
[70] Lee HS, Kim HJ, Choi S, Kim CK, Lee NS, Lee KT, et al. A 
case of type B lactic acidosis in acute leukemia. Yonsei Med 
J. 2010; 51(3): 460-2. 
http://dx.doi.org/10.3349/ymj.2010.51.3.460 
[71] Gardner AJ, Griffiths J. A case of type B lactic acidosis as a 
complication of chronic myelomonocytic leukaemia: a case 
report and review of the literature. J Med Case Rep. 2015; 9: 
16. 
http://dx.doi.org/10.1186/1752-1947-9-16 
[72] Chang H, Shuai X, Ma HB, Liu T. A case report of acute 
lymphoblastic leukemia complicated by lactic acidosis. Int J 
Hematol. 2010; 92(3): 538-41. 
http://dx.doi.org/10.1007/s12185-010-0685-7 
[73] Hoogwerf D, van Doorn J, Maartense E. The insulin-like 
growth factor-system in a patient with diffuse large B-cell 
non-Hodgkin's lymphoma and lactic acidosis. Ann Clin 
Biochem. 2013; 50(Pt 2): 169-72. 
http://dx.doi.org/10.1258/acb.2012.012125 
[74] Ruiz JP, Singh AK, Hart P. Type B lactic acidosis secondary 
to malignancy: case report, review of published cases, 
insights into pathogenesis, and prospects for therapy. 
Scientific World Journal. 2011; 11: 1316-24. 
http://dx.doi.org/10.1100/tsw.2011.125 
[75] Koppenol WH, Bounds PL, Dang CV. Otto Warburg's 
contributions to current concepts of cancer metabolism. Nat 
Rev Cancer. 2011; 11(5): 325-37. 
http://dx.doi.org/10.1038/nrc3038 
[76] Glasheen JJ, Sorensen MD. Burkitt's lymphoma presenting 
with lactic acidosis and hypoglycemia - a case presentation. 
Leuk Lymphoma. 2005; 46(2): 281-3. 
http://dx.doi.org/10.1080/10428190400016723 
[77] Diaz J, Antoine J, Azad N. A case of hypoglycemia, lactic 
acidosis, and hematologic malignancy. Endocr Pract. 2010; 
16(2): 241-3. 
http://dx.doi.org/10.4158/EP09183.CR 
[78] Claudino WM, Dias A, Tse W, Sharma VR. Type B lactic 
acidosis: a rare but life threatening hematologic emergency. 
A case illustration and brief review. Am J Blood Res. 2015; 
5(1): 25-9. 
[79] Nott L, Price TJ, Pittman K, Patterson K, Fletcher J. 
Hyperammonemia encephalopathy: an important cause of 
neurological deterioration following chemotherapy. Leuk 
Lymphoma. 2007; 48: 1702-1711. 
http://dx.doi.org/10.1080/10428190701509822 
[80] Kwan L, Wang C, Levitt L. Hyperammonemic 
encephalopathy in multiple myeloma. N Engl J Med. 2002; 
346: 1674-1675. 
http://dx.doi.org/10.1056/NEJM200205233462119 
[81] Fine P, Adler K, Gerstenfeld D. Idiopathic hyperammonemia 
after high dose chemotherapy (letter). Am J Med 1989; 86(5): 
629. 
http://dx.doi.org/10.1016/0002-9343(89)90406-3 
[82] Tse N, Cederbaum S, Glaspy JA. Hyperammonemia 
following allogeneic bone marrow transplantation. Am J 
Hematol 1991; 38(2): 140-1. 
http://dx.doi.org/10.1002/ajh.2830380213 
[83] Ho AY, Mijovic A, Pagliuca A, Mufti GJ. Idiopathic 
hyperammonaemia syndrome following allogeneic peripheral 
blood progenitor cell transplantation (allo-PBPCT). Bone 
Marrow Transplant. 1997; 20(11): 1007-8. 
http://dx.doi.org/10.1038/sj.bmt.1701003 
[84] Chen YH, Chiou TJ, Hsu YN, Liu CY. Idiopathic 
hyperammonemia after chemotherapy with vinorelbine, 
topotecan, and cisplatin in a patient with acute lymphocytic 
leukemia. Hematol Oncol Stem Cell Ther. 2010; 3(4): 199-
202. 
http://dx.doi.org/10.5144/1658-3876.2010.199 
[85] Nott L, Price TJ, Pittman K, Patterson K, Young R, Fletcher 
J.Hyperammonaemic encephalopathy associated with 
rituximab-containing chemotherapy. Intern Med J. 2008; 
38(10): 800-3. 
[86] Laemmle A, Hahn D, Hu L, Rüfenacht V, Gautschi M, 
Leibundgut K, et al. Fatal hyperammonemia and carbamoyl 
phosphate synthetase 1 (CPS1) deficiency following high-
dose chemotherapy and autologous hematopoietic stem cell 
transplantation. Mol Genet Metab. 2015; 114(3): 438-44. 
http://dx.doi.org/10.1016/j.ymgme.2015.01.002 
[87] Clay AS, Hainline BE. Hyperammonemia in the ICU. Chest. 
2007; 132(4): 1368-78. 
http://dx.doi.org/10.1378/chest.06-2940 
[88] Kaveggia FF, Thompson JS, Schafer EC, et al. 
Hyperammonemic encephalopathy in urinary diversion with 
urea-splitting urinary tract infection. Arch Intern Med 1990; 
150: 2389-2392. 
http://dx.doi.org/10.1001/archinte.1990.00390220121025 
[89] Olde Damink SW, Dejong CH, Deutz NE, et al. Upper 
gastrointestinal bleeding: an ammoniagenic and catabolic 
event due to the total absence of isoleucine in the 
haemoglobin molecule. Med Hypotheses 1999; 52: 515-519 
http://dx.doi.org/10.1054/mehy.1998.0026 
[90] Felig DM, Brusilow SW, Boyer JL. Hyperammonemic coma 
due to parenteral nutrition in a woman with heterozygous 
ornithine transcarbamylase deficiency. Gastroenterology 
1995; 109: 282-284 
http://dx.doi.org/10.1016/0016-5085(95)90295-3 
[91] Prado FA, Delfino VD, Grion CM, de Oliveira JA. 
Hyperammonemia in ICU patients: a frequent finding 
associated with high mortality. J Hepatol. 2015; 62(5): 1216-
8. 
http://dx.doi.org/10.1016/j.jhep.2015.01.009 
[92] Daniotti M, la Marca G, Fiorini P, Filippi L. New 
developments in the treatment of hyperammonemia: 
emerging use of carglumic acid. Int J Gen Med. 2011; 4: 21-
8. 
[93] Ellison DH, Berl T. The syndrome of inappropriate 
antidiuresis. N Engl J Med. 2007; 356: 2064-2072. 
http://dx.doi.org/10.1056/NEJMcp066837 
[94] Raftopoulos H. Diagnosis and management of hyponatremia 
in cancer patients. Support Care Cancer. 2007; 15: 1341-
1347. 
http://dx.doi.org/10.1007/s00520-007-0309-9 
[95] Simeen Akhtar, Edmund Cheesman, and Edward B Jude. 
SIADH and partial hypopituitarism in a patient with 
intravascular large B-cell lymphoma: a rare cause of a 
common presentation. BMJ Case Rep. 2013; 2013: 
bcr2012007147. 
[96] Chong-Gui Zhu, Qiu-Zi Zhang, Mei Zhu, Qiong-Li Zhai, Xiao-
Yu Liang, Zong-Hong Shao, et al. A case report of syndrome 
of inappropriate antidiuretic hormone secretion with 
Castleman's disease and lymphoma BMC Endocr Disord. 
2013; 13: 19. 
http://dx.doi.org/10.1186/1472-6823-13-19 
[97] Demirkan F, Vural F, Ozsan GH, Ozcan MA, Ozkal S, Undar 
B. Hemophagocytic syndrome associated with inappropiate 
secretion of antidiuretic hormone in lymphoma and acute 
myeloblastic leukemia: report of two cases. Leuk Lymphoma. 
2001; 42(6): 1401-4. 
http://dx.doi.org/10.3109/10428190109097769 
[98] Kobayashi R, Iguchi A, Nakajima M, Sato T, Yoshida M, 
Kaneda M, et al. Hyponatremia and syndrome of 
inappropriate antidiuretic hormone secretion complicating 
stem cell transplantation. Bone Marrow Transplant. 2004; 
34(11): 975-9. 
http://dx.doi.org/10.1038/sj.bmt.1704688 
[99] Wei J, Xiao Y, Yu X, Zhou J, Zhang Y. Early onset of 
syndrome of inappropriate antidiuretic hormone secretion 
(SIADH) after allogeneic haematopoietic stem cell 
transplantation: case report and review of the literature. J Int 
36    World Journal of Oncology Research, 2015, Vol. 2 Carella et al. 
Med Res. 2010; 38(2): 705-10. 
http://dx.doi.org/10.1177/147323001003800235 
[100] Michelle Baker, Maurie Markman, and Jiaxin Niu. 
Cyclophosphamide-Induced Severe Acute Hyponatremic 
Encephalopathy in Patients with Breast Cancer: Report of 
Two Cases. Case Rep Oncol. 2014; 7(2): 550-554. 
http://dx.doi.org/10.1159/000365832 
[101] Dalia A. Hamdy, Hager El-Geed, Samah El-Salem, and 
Manal Zaidan. Posaconazole-Vincristine Coadministration 
Triggers Seizure in a Young Female Adult: A Case Report. 
Case Rep Hematol. 2012; 2012: 343742. 
http://dx.doi.org/10.1155/2012/343742 
[102] Peter Gross. Clinical management of SIADH. Ther Adv 
Endocrinol Metab. 2012; 3(2): 61-73. 
http://dx.doi.org/10.1177/2042018812437561 
[103] Eline A Dubois, Robert Rissmann, Adam F Cohen. 
Tolvaptan. Br J Clin Pharmacol. 2012; 73(1): 9-11. 
http://dx.doi.org/10.1111/j.1365-2125.2011.04029.x 
[104] Purav R. Bhatt, Elizabeth B. McNeely, Tess E. Lin, Kirkwood 
F. Adams, Jr., J. Herbert Patterson. Review of Tolvaptan's 
Pharmacokinetic and Pharmacodynamic Properties and Drug 
Interactions. J Clin Med. 2014; 3(4): 1276-1290. 
http://dx.doi.org/10.3390/jcm3041276 
[105] Jorge J. Castillo, Marc Vincent, Eric Justice. Diagnosis and 
Management of Hyponatremia in Cancer Patients. 
Oncologist. 2012; 17(6): 756-765. 
http://dx.doi.org/10.1634/theoncologist.2011-0400. 
 
Received on 07-08-2015 Accepted on 04-09-2015 Published on 18-09-2015 
 
 
© 2015 Carella et al.; Licensee Cosmos Scholars Publishing House. 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, 
provided the work is properly cited. 
 
 
